Background/Objectives: The role of iron in Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) has been debated. However, the effects of iron on protein burden in these diseases remain poorly elucidated. We hypothesized that there is an association between iron deposition and tau and beta-amyloid deposition in deep grey matter (GM) regions in FTLD. Methods: Neuropathological samples were collected from two control subjects and 10 disease subjects. This included 12 subjects, with several pathological subgroups represented by only one or two cases. Of the 10 disease subjects, one had low-level AD neuropathology (L-AD), and one had high-level AD neuropathology (H-AD), whereas the remaining eight subjects had FTLD-tau pathology, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), globular glial tauopathy (GGT), and Pick’s disease (PiD). Neuropathological samples were stained for iron with Prussian blue (PB) and ferritin, tau, and beta-amyloid in the basal ganglia (BG). All 12 subjects had also undergone diffusion MRI, amyloid-PET (PiB-PET), and Tau-PET (flortaucipir) before death. Diffusion tensor imaging mean diffusivity (MD) from BG was examined in each subject. Spearman’s rank correlations between imaging and histology were calculated. Results: Increased BG iron was observed in PSP subjects. Prussian blue and ferritin measures were associated with higher tau- and β-amyloid pathological burden. Tau-PET uptake correlated with iron in the BG. Conclusions: The results of this exploratory study suggest associations between iron burden and tau- and β-amyloid-related measures within basal ganglia regions that may help to explain increased PET signals in AD and FTLD-Tau. Our findings should be considered to be hypothesis-generating and require validation. These preliminary findings require validation in larger cohorts.
Alzheimer’s disease (AD) is a multifactorial disease with several key hypotheses centred around its pathological hallmarks, including amyloid and tau and other mechanisms, such as vascular dysfunction. Revised criteria for AD diagnosis reflects these hypotheses and includes white matter hyperintensities (WMH) as a bi...
N. Rambarack, T. Lashley, J. Barnes et al.· Alzheimer's Research & T...· 0 citations
MRI measures of cerebral blood flow and white matter hyperintensities differentiated NDAN from AD+MCI, highlighting vascular contributions to cognitive resilience, and CBF differentiated AD+MCI from Controls.
S. Fernandes‐Taylor, I. Driscoll, M. Glittenberg et al.· medRxiv· 0 citations
OBJECTIVE
Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease (AD), with significant pathological overlap between the two conditions. However, the impact of Alzheimer's co-pathology on basal forebrain (BF) atrophy and its relationship with neurodegeneration and...
Daniele Urso, Thomas Giannelli, B. Tafuri et al.· Annals of Neurology· 0 citations
Higher baseline BG-EPVS burden was associated with a more sustained rate of amyloid-β accumulation among participants with high baseline amyloid burden, and the annual rate of change in FBP SUVR follows an inverted U-shaped relationship with baseline FBP SUVR.
Ling-Yun Liu, Qing-Ze Zeng, Xiao Luo et al.· Academic Radiology· 0 citations
Dementia epileptica was associated with increased pTau burden in the epileptogenic hemisphere and time since diagnosis supporting the concept of seizure-induced pTau accumulation, however, pTau is unlikely to be the primary neuropathological link between epilepsy and dementia in the cohort studied given the overall mil...
Silke Emilie Laustsen, Janette Krogh Petersen, C. D. Cornwall et al.· Epilepsy Research· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting more than 55 million people worldwide and is characterized by cognitive decline, amyloid-beta (Aβ) plaques, and neurofibrillary tangles. Although transgenic rodent models have advanced understanding of AD, they do not fully replicate the spo...
Abdullatif Alsulami, Marika Bogdani, Evan L. MacLean et al.· npj Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.